Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Shujiro Tsuji
Based on 9 articles published since 2010
(Why 9 articles?)
||||

Between 2010 and 2020, Shujiro Tsuji wrote the following 9 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review [The strategy of pancreatic cancer for early detection]. 2015

Sofuni, Atsushi / Itoi, Takao / Tsuchiya, Takayoshi / Tsuji, Shujiro / Kamada, Kentaro / Ikeuchi, Nobuhito / Tanaka, Reina / Umeda, Junko / Tonozuka, Ryosuke / Honjo, Mitsuyoshi / Mukai, Shuntaro / Fujita, Mitsuru / Yamamoto, Kenjiro / Moriyasu, Fuminori. ·Department of Gastroenterology and Hepatology, Tokyo Medical University. ·Nihon Shokakibyo Gakkai Zasshi · Pubmed #26250128.

ABSTRACT: -- No abstract --

2 Article Evaluation of novel slim biopsy forceps for diagnosis of biliary strictures: Single-institutional study of consecutive 360 cases (with video). 2017

Yamamoto, Kenjiro / Tsuchiya, Takayoshi / Itoi, Takao / Tsuji, Shujiro / Tanaka, Reina / Tonozuka, Ryosuke / Honjo, Mitsuyoshi / Mukai, Shuntaro / Kamada, Kentaro / Fujita, Mitsuru / Asai, Yasutsugu / Matsunami, Yukitoshi / Nagakawa, Yuichi / Yamaguchi, Hiroshi / Sofuni, Atsushi. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan. · Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan. itoi@tokyo-med.ac.jp. · Third Department of Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan. · Department of Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan. ·World J Gastroenterol · Pubmed #29085192.

ABSTRACT: AIM: To evaluate the feasibility and reliability of endoscopic transpapillary bile duct biopsy for the diagnosis of biliary strictures. METHODS: A total of 360 patients (241 men) who underwent endoscopic retrograde cholangiopancreatography for biliary strictures with biopsy from April 2012 to March 2016 at Tokyo Medical University Hospital were retrospectively reviewed. This study was approved by our Institutional Review Board (No. 3516). Informed consent was obtained from all individual participants included in this study. The biopsy specimens were obtained using a novel slim biopsy forceps (Radial Jaw 4P, Boston Scientific, Boston, MA, United States). RESULTS: The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 69.6%, 100%, 100%, 59.1%, and 78.8%, respectively. The sensitivity was 75.6% in bile duct cancer, 64% in pancreatic cancer, 61.1% in gallbladder cancer, and 57.1% in metastasis. In bile duct cancer, a lower sensitivity was observed for perihilar bile duct stricture (68.7%) than for distal bile duct stricture (83.1%). In terms of the stricture lengths of pancreatic cancer, gallbladder cancer, and metastasis, a longer stenosis resulted in a better sensitivity. In particular, there was a significant difference between pancreatic cancer and gallbladder cancer ( CONCLUSION: Endoscopic transpapillary biopsy alone using novel slim biopsy forceps is feasible and reliable, but restrictive. Biopsy should be performed in consideration of the stricture level, stricture length, and cancer type.

3 Article Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. 2017

Itoi, Takao / Sugimoto, Masahiro / Umeda, Junko / Sofuni, Atsushi / Tsuchiya, Takayoshi / Tsuji, Shujiro / Tanaka, Reina / Tonozuka, Ryosuke / Honjo, Mitsuyoshi / Moriyasu, Fuminori / Kasuya, Kazuhiko / Nagakawa, Yuichi / Abe, Yuta / Takano, Kimihiro / Kawachi, Shigeyuki / Shimazu, Motohide / Soga, Tomoyoshi / Tomita, Masaru / Sunamura, Makoto. ·Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. itoi@tokyo-med.ac.jp. · Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan. msugi@sfc.keio.ac.jp. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. junko.umeda@gmail.com. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. a-sofuni@amy.hi-ho.ne.jp. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. tsuchiya623@mac.com. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. g.shujiro@gmail.com. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. onakasuicyatta@yahoo.co.jp. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. tonozuka1978@gmail.com. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. honjo3244@yahoo.co.jp. · Division of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. moriyasu@tokyo-med.ac.jp. · Third Department of Surgery, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. kasuya-k@jcom.home.ne.jp. · Third Department of Surgery, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan. naga@tokyo-med.ac.jp. · Fourth Department of Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji,Tokyo 193-0998, Japan. abey3666@gmail.com. · Fourth Department of Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji,Tokyo 193-0998, Japan. kiminoriman526@yahoo.co.jp. · Fourth Department of Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji,Tokyo 193-0998, Japan. skawachi@tokyo-med.ac.jp. · Fourth Department of Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji,Tokyo 193-0998, Japan. shimazu2401@yahoo.co.jp. · Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan. soga@sfc.keio.ac.jp. · Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata 997-0052, Japan. mt@sfc.keio.ac.jp. · Fourth Department of Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji,Tokyo 193-0998, Japan. be7@xui.biglobe.ne.jp. ·Int J Mol Sci · Pubmed #28375170.

ABSTRACT: This study evaluated the clinical use of serum metabolomics to discriminate malignant cancers including pancreatic cancer (PC) from malignant diseases, such as biliary tract cancer (BTC), intraductal papillary mucinous carcinoma (IPMC), and various benign pancreaticobiliary diseases. Capillary electrophoresismass spectrometry was used to analyze charged metabolites. We repeatedly analyzed serum samples (

4 Article Endoscopic ultrasound-guided choledochoantrostomy as an alternative extrahepatic bile duct drainage method in pancreatic cancer with duodenal invasion. 2013

Itoi, Takao / Itokawa, Fumihide / Tsuchiya, Takayoshi / Tsuji, Shujiro / Tonozuka, Ryosuke. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan. itoi@tokyo-med.ac.jp ·Dig Endosc · Pubmed #23617666.

ABSTRACT: Recently, endoscopic ultrasonography-guided bile duct drainage (EUS-BD) has become popular as an alternative method of biliary drainage in cases of failed endoscopic retrograde cholangiopancreatography. In terms of EUS-guided extrahepatic bile duct drainage, recently, EUS-guided choledochoantrostomy has been reported as a variation of EUS-BD. We describe a case of successful choledochoantrostomy using a fully covered self-expandable metallic stent. We conclude that EUS-guided choledochoantrostomy should be one option for biliary decompression. In particular, if patients have duodenal strictures, with or without a duodenal metal stent, it seems to be an ideal alternative to choledochoduodenostomy.

5 Article Novel biopsy forceps for diagnosis of biliary tract diseases during endoscopic retrograde cholangiopancreatography: a prospective comparative study with 90° adjustable and conventional biopsy forceps. 2012

Ishii, Kentaro / Itoi, Takao / Sofuni, Atsushi / Itokawa, Fumihide / Tsuchiya, Takayoshi / Kurihara, Toshio / Tsuji, Shujiro / Ikeuchi, Nobuhito / Umeda, Junko / Moriyasu, Fuminori. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan. ishiken@tokyo-med.ac.jp ·Hepatogastroenterology · Pubmed #22094996.

ABSTRACT: BACKGROUND/AIMS: Recently, controllable biopsy forceps (MTW, D°sseldorf, Germany) have been developed. This biopsy forceps were 90° adjustable. In the present study, the feasibility and efficacy of the controllable biopsy forceps were compared with those of conventional biopsy forceps in patients with biliary tract disease. METHODOLOGY: A total of 27 patients with biliary tract lesions were enrolled. We evaluated the procedure time, the sample tissue size and the diagnostic accuracy. In addition, the physicians performing the procedure rated their impressions about operability into 3 classes: excellent, fair and poor. RESULTS: The sensitivity in distinguishing benign from malignant lesions was 71.4% (15/21) for the 90° adjustable type and 66.7% (14/21) for the conventional type. The accuracy rate was 77.8% (21/27) for the 90° adjustable type and 74.0% (20/27) for the conventional type. In terms of operability as rated by each physician, the 'excellent' rate was given more frequently to the 90° adjustable type 25.9% than for the conventional type 11.1% (p=0.047). CONCLUSIONS: This preliminary study showed that controllable biopsy forceps compared to conventional type biopsy forceps, despite a larger diameter, enables biopsy in a similar procedure time and its ease of use was rated better.

6 Article Histological diagnosis by EUS-guided fine-needle aspiration biopsy in pancreatic solid masses without on-site cytopathologist: a single-center experience. 2011

Itoi, Takao / Tsuchiya, Takayoshi / Itokawa, Fumihide / Sofuni, Atsushi / Kurihara, Toshio / Tsuji, Shujiro / Ikeuchi, Nobuhito. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan. itoi@tokyo-med.ac.jp ·Dig Endosc · Pubmed #21535198.

ABSTRACT: There are few reports on the histological diagnostic ability of endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) in a large-series of pancreatic masses. In the present study therefore we retrospectively evaluated the histological diagnostic ability of EUS-FNA in pancreatic masses without on-site cytopathologist. In 355 patients with pancreatic solid masses, EUS-FNA was carried out. EUS-FNA histology showed accuracy, 90.7%; sensitivity, 89.5%; specificity, 95.6%; positive predict value, 98.8%; negative predict value, 68.8% by intention-to-treat analysis. Except for 10 with inadequate materials, EUS-FNA histology showed accuracy, 93.3%; sensitivity, 91.8%; specificity, 100%; positive predict value, 100%; negative predict value, 77.6%. The mean number of puncture was 2.88 (range 1 to 8). There was two (0.6%) procedure-related bleeding. In conclusion, diagnostic ability of EUS-FNA by histological materials was similar to previous literature on the EUS-FNA without on-site cytopathologist.

7 Article EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. 2011

Itokawa, Fumihide / Itoi, Takao / Sofuni, Atsushi / Kurihara, Toshio / Tsuchiya, Takayoshi / Ishii, Kentaro / Tsuji, Shujiro / Ikeuchi, Nobuhito / Umeda, Junko / Tanaka, Reina / Yokoyama, Naoyuki / Moriyasu, Fuminori / Kasuya, Kazuhiko / Nagao, Toshitaka / Kamisawa, Terumi / Tsuchida, Akihiko. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. ·J Gastroenterol · Pubmed #21505859.

ABSTRACT: BACKGROUND: Recently, the usefulness of endoscopic ultrasound (EUS) elastography has been reported for the diagnosis of pancreatic lesions. In the present study, we retrospectively assessed EUS elastography as a diagnostic tool by evaluating tissue elasticity distribution and elasticity semiquantification, using the strain ratio (SR) of tissue elasticity, in patients with pancreatic masses. METHODS: One hundred and nine patients who underwent EUS elastography between September 2006 and May 2009 were retrospectively evaluated. The final diagnosis was chronic pancreatitis (CP) in 20 patients [6 with non-mass-forming pancreatitis, 7 with mass-forming pancreatitis (MFP), and 7 with autoimmune pancreatitis (AIP)], pancreatic cancer (PC) in 72, pancreatic neuroendocrine tumor (PNET) in 9, and normal pancreas in 8. The tissue elasticity distribution calculation was performed in real time, and the results were represented in color in fundamental B-mode imaging. In addition, we performed quantification using the SR (non-mass area/mass area). RESULTS: Elastography for all PC patients showed intense blue coloration, indicating malignant lesions. In contrast, MFP presented with a mixed coloration pattern of green, yellow, and low-intensity blue. Normal controls showed an even distribution of green to red. The mean SR was 23.66 ± 12.65 for MFP and 39.08 ± 20.54 for PC (P < 0.05). CONCLUSIONS: Endoscopic ultrasound elastography is a promising diagnostic tool for defining the tissue characteristics of pancreatic masses. In addition, semiquantitative analysis of elasticity using the SR may allow the differentiation of MFP from PC.

8 Article The current potential of high-intensity focused ultrasound for pancreatic carcinoma. 2011

Sofuni, Atsushi / Moriyasu, Fuminori / Sano, Takatomo / Yamada, Kota / Itokawa, Fumihide / Tsuchiya, Takayoshi / Tsuji, Shujiro / Kurihara, Toshio / Ishii, Kentaro / Itoi, Takao. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. a-sofuni@amy.hi-ho.ne.jp ·J Hepatobiliary Pancreat Sci · Pubmed #21360084.

ABSTRACT: INTRODUCTION: Pancreatic carcinoma has one of the poorest prognoses among malignant tumors. Many pancreatic carcinoma patients who undergo common treatments, such as surgery, radio-chemotherapy and chemotherapy, gained little benefit because of the histological characteristics. MATERIALS AND METHODS: HIFU is a new technique of noninvasive treatment for unresectable pancreatic carcinoma. HIFU has the ability to ablate the deep tissues inside body from an external source using high-intensity focused ultrasound. The effects of HIFU can result in cell destruction and tissue necrosis. RESULTS: Results from study in China in 251 patients with advanced pancreatic carcinoma suggested that HIFU treatment could reduce the size of tumors without causing complications and prolong survival. Moreover, according to some reports from China, HIFU treatment is suggested to be useful as the one of palliative treatments for unresectable pancreatic carcinoma. Our case of HIFU therapy for pancreatic carcinoma is presented including pathological findings in this paper. The results suggested that HIFU treatment might be effective in controlling local tumor. CONCLUSION: HIFU therapy may have the possibility of becoming one of the combination therapies for treating pancreatic carcinoma in the future.

9 Article Prognosis of cancer with branch duct type IPMN of the pancreas. 2010

Ikeuchi, Nobuhito / Itoi, Takao / Sofuni, Atsushi / Itokawa, Fumihide / Tsuchiya, Takayoshi / Kurihara, Toshio / Ishii, Kentaro / Tsuji, Shujiro / Umeda, Junko / Moriyasu, Fuminori / Tsuchida, Akihiko / Kasuya, Kazuhiko. ·Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjyuku, Shinjyuku-ku, Tokyo 160-0023, Japan. ·World J Gastroenterol · Pubmed #20397268.

ABSTRACT: AIM: To examine the coexistence of metachronous and synchronous cancer in branch duct intraductal papillary mucinous neoplasms of the pancreas (IPMN). METHODS: We reviewed the records of 145 patients with branch duct IPMN between January 1991 and April 2008 and assessed the relationship between IPMN and intra- or extra-pancreatic carcinoma and the outcome of IPMN. RESULTS: The mean observation period was 55.9 +/- 45.3 mo. Among the 145 patients, the frequency of extra-pancreatic cancer was 29.0%. The frequency of gastric cancer, colon cancer, breast cancer, and pancreatic cancer were 25.5%, 15.7%, 13.7%, and 9.8%, respectively. Twenty (13.8%) of the patients died. The cause of death was extra-pancreatic carcinoma in 40%, pancreatic cancer in 25%, IPMN per se in 20%, and benign disease in 15% of the patients. CONCLUSION: The prognosis for IPMN depends not on the IPMN per se, but on the presence of intra- or extra-pancreatic cancer.